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Abstract
Background: Kawasaki disease is an acute, febrile, self-limiting, inflammatory systemic vasculitis seen in early
childhood, most commonly in those below 5 years of age. In Kawasaki disease, the coronary arteries are most
commonly affected, which may lead to asymptomatic coronary artery ectasia or formation of an aneurysm.
Paroxysmal supraventricular tachycardia(PSVT) is a severe and rare cardiovascular complication of Kawasaki disease.
A case of Kawasaki disease presenting with unusual findings, including subdural effusion and PSVT is reported.
Case presentation: This is a 4-month-10-day-old boy presents with anterior fontanelle bulging and moderate
bilateral subdural effusion at the acute stage of Kawasaki disease and PSVT at the subacute stage of Kawasaki
disease. The subdural effusion was resolution after intravenous immunoglobulin(IVIG) administration. And the PSVT
was subsided after administered 3 doses of adenosine, 1 dose of amiodarone loading and Propranolol twice per
day use. At 1-year follow-up has made a complete recovery with no arrhythmia episodes, developmental effects
or abnormal neurologic findings.
Conclusion: Subdural effusion in the acute stage of Kawasaki disease may be an inflammatory response. It may
resolves spontaneously after anti-inflammatory treatment such as IVIG infusion. PSVT is a severe cardiovascular
complication of Kawasaki disease. In those who taking aspirin, we need to carefully observe the heart rhythm and
PSVT side effects, especially in the first month.
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Background
Kawasaki disease is an acute, febrile, self-limiting sys-
temic vasculitis seen in early childhood, most com-
monly in those below 5 years of age. This condition is
the leading cause of acquired heart disease in children
[1]. There are no specific biomarkers for the diagnosis
of Kawasaki disease.
The diagnostic criteria of typical Kawasaki disease
include fever lasting for 5 days in addition to 4 of the
following 5 clinical features: oropharyngeal changes; non-
purulent conjunctivitis; acute cervical lymphadenopathy
with lymph node diameter > 1.5 cm; peripheral extremity
changes; or a generalized polymorphous rash [2, 3].
In Kawasaki disease, the coronary arteries are most
commonly affected, which may lead to asymptomatic
coronary artery ectasia or formation of an aneurysm.
Rarely, Kawasaki disease may cause myocarditis, peri-
carditis, or lead to arrhythmias. Ventricular arrhythmia
is also an unusual finding in Kawasaki disease in the
past case presentation or literature review. Kawasaki
disease is a systemic inflammatory disease commonly
associated with thrombocytosis, especially after the first
week of illness [4]. The incidence of Kawasaki disease with
neurological complications is approximately 1.1-3.7 %.
Subdural fluid collection is rarely described in association
with Kawasaki disease in the previous literature.
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Full doses of intravenous immunoglobulin (IVIG) are
the mainstay of treatment. Early administration of IVIG
may reduce the risk of cardiac involvement to 5 % [5].
During the clinical course, close monitoring of cardio-
vascular function and coronary artery diameter is neces-
sary. For coronary artery abnormalities, aspirin is part of
the standard treatment [5]. In most children, the heart
problems subside after 5 or 6 weeks without lasting
damage. However, in some children, the coronary arter-
ies are damaged permanently.
Case presentation
The 4-month-10-day-old boy presented with intermit-
tent fever for 2 days and he was taken to emergency
department on February 16, 2014. He had received a 10-
valent pneumococcal vaccine (PCV 10), 2 days prior to
his visit, in a local clinic and did not have a fever or
throat injection at the time. After admission, physical
examination revealed injected throat and tonsils, coarse
breathing sounds, polymorphous rashes over the trunk,
anterior fontanelle bulging, and poor activity while fe-
brile. Laboratory examination revealed leukocytosis
(WBC: 28300/uL), segmented predominance (segment:
67 %) and an elevated CRP level (CRP: 69.4 mg/L).
Urine analysis showed mild pyuria (WBC: 12/uL) and
ketones (ketone: 40 mg/dL). He was admitted to the
hospital for suspected bacterial meningitis, and antibiotic
therapy with cefotaxime was started. However, his par-
ents declined our suggestion for cerebrospinal fluid
(CSF) tapping.
Persistent intermittent fever was noted on February
17, 2014. In addition, he presented with injected and fis-
sured lips, a strawberry tongue, erythema and edema
over palms and soles, and bilateral bulbar conjunctival
injection. The echocardiography was performed for
possible Kawasaki disease on February 17, 2014 and re-
vealed the z-score of the left coronary artery and right
coronary artery was 1.25 and 1.83, no coronary artery
dilatation complication. Swelling with erythematous
change over the Bacillus Calmette-Guérin vaccine
(BCG) injection site was noted on February 18, 2014.
Brain ultrasound (Fig. 1) was also performed for anter-
ior fontanelle bulging on February 18, 2014 and re-
vealed moderate subdural fluid collection.
Due to persistent intermittent fever for 5 days, on
February 18, 2014, IVIG therapy (IVIG 2 g/kg adminis-
tered over 12 h) was prescribed from that afternoon
until the next morning. Aspirin 30 mg once per day was
prescribed starting February 19, 2014. Fever subsided
gradually from February 21, 2014, following which low-
dose aspirin was continued. The symptoms of poly-
morphous rash, injected and fissured lips, and BCG
injection site swelling showed improvement. The pa-
tient was discharged without any discomfort or fever
on February 25, 2014.
The patient experienced a fever of 38.9 °C again on
March 5, 2014 in the early morning hours, and then
subsided spontaneously. In addition, a mildly injected
lip and distal limbs swelling without desquamation
were noted. Tachyarrhythmia (heart rate > 200 beats/
min) was present at the afternoon. Electrocardiogram
(ECG) (Fig. 2) showed PSVT. The echocardiography re-
vealed tachycardia with the z-score of the left coronary
artery and right coronary artery was 2.5 and 1.94, no
evidence of coronary artery dilatation, no ischemic
change, and no other abnormal findings. Laboratory
Fig. 1 Brain ultrasound. Initial brain ultrasound on admission with moderate subdural fluid collection(1.01 cm)
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examination showed leukocytosis (WBC: 17300/uL),
thrombocytosis (platelet: 820000/uL), an elevated CRP level
(CRP: 117.4 mg/L), an elevated ESR level (ESR: 108 mm/h),
and normal cardiac enzymes. The ECG monitor persist-
ently showed PSVT, even when the patient did not have a
fever and was not crying. We administered 3 doses of ad-
enosine (1 mg, 1 mg, and 2 mg intravenous push). His
heart rate was lowered to 60 beats/min with adenosine ad-
ministration, but was refractory soon after crying and being
in an irritable mood. Therefore, we initiated an amiodarone
loading dose of 5 mg/kg (40 mg in 20 ml of D5W) for 1 h.
Following this patient’s condition improved and was rela-
tively stable; the ECG monitor showed tachyarrhythmia
(heart rate 150–160 beats/min) with the P wave. Propran-
olol 2.5 mg twice per day was also prescribed for control of
the arrhythmic heart rate, after which, tachyarrhythmia was
improved with a baseline heart rate of 125–135 beats/min.
The repeat ECG (Fig. 3) showed a normal sinus rhythm
with normal PR and QT intervals and no delta waves.
Brain ultrasound (Fig. 4) performed on March 6, 2014
revealed mild subdural fluid collection. Blood, urine, and
CSF cultures were sterile. Because CSF microscopic ana-
lysis showed no pleocytosis, with normal sugar, protein,
and chloride levels, bacterial meningitis was less likely.
Desquamation on tips of fingers and toes appeared on
March 8, 2014. The echocardiography performed on
March 10, 2014 revealed a normal echocardiogram with
normal coronary arteries. We stopped propranolol use
on March 14, 2014. The patient was discharged on
March 15, 2014, as his general condition had improved,
and his vital signs were relatively stable.
The patient had regular follow-up examinations at the
pediatric outpatient department. The echocardiography
revealed a normal echocardiogram and normal coronary
arteries. ECG also showed a normal sinus rhythm. He
had taken aspirin for 2 months, which was discontinued
on April 21, 2014. Brain ultrasound revealed complete
resolution of the subdural effusion. No more arrhythmia
episodes, developmental effects or abnormal neurologic
findings were detected at the 1-year follow-up.
Discussion
Subdural effusion in Kawasaki disease
The incidence of Kawasaki disease with neurological
complications is approximately 1.1-3.7 %. Nervous sys-
tem complications previously reported include seizure,
facial nerve palsy, meningoencephalitis, hemiplegia,
ataxia, chorea, ischemia, abnormal vision, disturbed
consciousness, behavioral changes, sensorineural hear-
ing loss, and monocyte-predominant pleocytosis in CSF
[6, 7]. Subdural fluid collection is rarely described in as-
sociation with Kawasaki disease. Only 7 equivocal cases
of extracerebral fluid collection or subdural effusion in
the acute stage of atypical Kawasaki disease have been
reported in the literature [8, 9].
Aoki et al. [8] reported the case of a 6-month-old girl
in the acute stage of Kawasaki disease, who presented
with retinal hemorrhage complications and bilateral
Fig. 2 Electrocardiogram. Initial ECG with paroxysmal supraventricular tachycardia
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subdural fluid collection with intracranial hypertension.
The subdural effusion with intracranial hypertension
was controlled using a subdural tap and glycerol adminis-
tration. Additionally, a computerized tomography (CT)
scan confirmed reduction of subdural fluid collection.
Bailie et al. [9] described the case of a 6-month-old
boy with possible Kawasaki disease, who had complica-
tions related to bilateral subdural collection and pro-
longed right-sided seizure. He also presented with
tachycardia (approximately 120–150 beats/min). The
patient had an amazing response to administration of
IVIG (2 g/kg) and high-dose aspirin (100 mg/kg/day in
4 divided doses). CT scan showed complete resolution
of the subdural collection at the 6-months follow-up.
Our patient is a typical case of Kawasaki disease with
moderate bilateral subdural effusion and is the youngest
one of all previously reported cases in previous litera-
ture. However, our patient only presented with anterior
Fig. 3 Electrocardiogram. ECG with normal sinus rhythm after 3 doses of adenosine, amiodarone loading dose of 5 mg/kg, and Propranolol.
Arrow mark: P waves
Fig. 4 Brain ultrasound. Follow-up brain ultrasound 2 weeks after IVIG administration showing mild subdural fluid collection(0.59 cm)
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fontanelle bulging and poor activity when febrile, with-
out any specific neurological signs or encephalopathy
symptoms. This patient underwent only IVIG adminis-
tration as an anti-inflammatory measure in the acute
stage of Kawasaki disease. Brain ultrasound revealed a
definite reduction in the volume of subdural effusion
2 weeks post-presentation and IVIG infusion. There was
no any lasting damage, and this child demonstrated nor-
mal development at the 1-year symptom-free follow-up.
PSVT in Kawasaki disease
The cardiovascular complications of Kawasaki syndrome
commonly include symptoms related to coronary artery
dilation, coronary aneurysm, myocarditis, or myocardial
ischemia. Ventricular arrhythmia is an unusual finding
and rare complication in the acute phase of Kawasaki
disease; this sign is independent of coronary artery in-
volvement in Kawasaki disease [10].
Haney et al. [11] reported a 2.5-year-old child with
ventricular arrhythmia in the acute stage of Kawasaki
disease. The arrhythmia was resolved after empirical
treatment with oral steroids.
Seymour et al. [12] described the case of a 12-year-old
girl with medical history of Kawasaki disease diagnosed at
the age 2 years and who received appropriate treatment
for this condition. The patient presented with supraven-
tricular tachycardia (SVT) at 180 beats/min. Intravenous
access and vagal maneuvers were performed to abate the
SVT without success. After 2 doses of adenosine was
administered by rapid intravenous bolus, the heartbeat
decreased to a sinus rhythm of 88 beats/min. No further
damage was noted during an outpatient follow-up.
Our patient is a typical and rare case of Kawasaki dis-
ease with PSVT. Tachyarrhythmia (heart rate > 200 beats/
min) and PSVT were presented after admission in the
subacute stage of Kawasaki disease, and our patient had
taken aspirin for only 2 weeks. It was difficult to control
his heart rate. We had attempted 3 doses of adenosine
(1 mg, 1 mg, and 2 mg intravenous push), and amiodarone
loading dose of 5 mg/kg (40 mg in 20 ml of D5W) for 1 h
to control the PSVT. Propranolol 2.5 mg twice per day
was added to control the arrhythmia. There were no signs
of any defects or damage on the ECG and echocardiog-
raphy at the 1-year follow-up.
IVIG in the subacute stage of Kawasaki disease
The clinical presentation of Kawasaki disease is conven-
tionally divided into 4 stages: acute, subacute, convalescent
and chronic. The subacute stage of Kawasaki disease be-
gins when the fever has abated, and it may last for 4–6
weeks. The rate of sudden death is the highest in the sub-
acute stage. Persistence of fever beyond 2–3 weeks in the
subacute stage of Kawasaki disease may be an indication of
recrudescent Kawasaki disease or persistent Kawasaki dis-
ease. This condition requires secondary IVIG therapy [13].
On the other hand, we have defined recurrent Kawa-
saki disease as a separate episode fulfilling Kawasaki
disease criteria after an earlier occurrence has fully
resolved, typically at least 2 months later [13]. The re-
currence rate was 6.89 per 1000 person-years, with a
high incidence within 12 months following the first epi-
sode [14]. Recurrent Kawasaki disease requires reevalua-
tion and retreatment with IVIG and aspirin. Patients
with recurrent Kawasaki disease are at an increased risk
for developing cardiac sequelae.
In our patient, the secondary fever episode subsided after
treatment with antipyretics, and the fever episode duration
was less than 24 h. It is obvious that the secondary fever
episode in our patient was not a case of recrudescent or re-
current Kawasaki disease. Therefore, our patient did not
need secondary IVIG infusion or retreatment. The only
intervention needed was symptom-control and monitoring
of further complications of Kawasaki disease.
Conclusions
We hereby present a young infant with IVIG-responsive
subdural effusion and difficult-to-control PSVT compli-
cations due to Kawasaki disease.
Subdural effusion in the acute stage of Kawasaki dis-
ease may be an inflammatory response. Administration
of IVIG relieves acute inflammation. As in our case,
there is no need for a subdural tap or any surgical
intervention; the subdural effusion resolves spontan-
eously after anti-inflammatory treatment such as IVIG
infusion. Additionally, there is no any lasting defect or
damage in patients with Kawasaki disease. PSVT is a
severe cardiovascular complication of Kawasaki disease
and may be related to sudden death or lasting damage
in the case of incomplete symptom control or inad-
equate treatment. In those who taking aspirin, we need
to carefully observe the heart rhythm and PSVT side ef-
fects, especially in the first month. A second fever episode
in a patient with Kawasaki disease should be differentially
diagnosed. If the fever occurs during the subacute stage of
Kawasaki disease and persists less than 2–3 weeks, it is
not a case of recrudescent Kawasaki disease or recurrent
illness. Treatment with secondary IVIG therapy or corti-
costeroids is therefore not requires.
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